Stem Cell Architecture Drives Myelodysplastic Syndrome Progression and Predicts Response to Venetoclax-Based Therapy

Through integrative molecular profiling of HSCs and progenitor cells in large patient cohorts, scientists found that myelodysplastic syndromes HSCs in two distinct differentiation states were maintained throughout the clinical course of the disease.